Literature DB >> 26771518

Antigen-Specific Binding of Multivalent Soluble Antigen Arrays Induces Receptor Clustering and Impedes B Cell Receptor Mediated Signaling.

Brittany L Hartwell1, Francisco J Martinez-Becerra2,3, Jun Chen3, Heather Shinogle4, Michelle Sarnowski5, David S Moore4, Cory Berkland1,3,5.   

Abstract

A pressing need exists for autoimmune disease therapies that act in an antigen-specific manner while avoiding global immunosuppression. Multivalent soluble antigen arrays (SAgAPLP:LABL), designed to induce tolerance to a specific multiple sclerosis autoantigen, consist of a flexible hyaluronic acid (HA) polymer backbone cografted with multiple copies of autoantigen peptide (PLP) and cell adhesion inhibitor peptide (LABL). Previous in vivo studies revealed copresentation of both signals on HA was necessary for therapeutic efficacy. To elucidate therapeutic cellular mechanisms, in vitro studies were performed in a model B cell system to evaluate binding and specificity. Compared to HA and HA arrays containing only grafted PLP or LABL, SAgAPLP:LABL displaying both PLP and LABL exhibited greatly enhanced B cell binding. Furthermore, the binding avidity of SAgAPLP:LABL was primarily driven by the PLP antigen, determined via flow cytometry competitive dissociation studies. Fluorescence microscopy showed SAgAPLP:LABL induced mature receptor clustering that was faster than other HA arrays with only one type of grafted peptide. SAgAPLP:LABL molecules also reduced and inhibited IgM-stimulated signaling as discerned by a calcium flux assay. The molecular mechanisms of enhanced antigen-specific binding, mature receptor clustering, and dampened signaling observed in B cells may contribute to SAgAPLP:LABL therapeutic efficacy.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26771518     DOI: 10.1021/acs.biomac.5b01097

Source DB:  PubMed          Journal:  Biomacromolecules        ISSN: 1525-7797            Impact factor:   6.988


  6 in total

1.  Multivalent Soluble Antigen Arrays Exhibit High Avidity Binding and Modulation of B Cell Receptor-Mediated Signaling to Drive Efficacy against Experimental Autoimmune Encephalomyelitis.

Authors:  Brittany L Hartwell; Chad J Pickens; Martin Leon; Cory Berkland
Journal:  Biomacromolecules       Date:  2017-05-17       Impact factor: 6.988

2.  Autoantigen Tetramer Silences Autoreactive B Cell Populations.

Authors:  Matthew A Christopher; Stephanie N Johnson; J Daniel Griffin; Cory J Berkland
Journal:  Mol Pharm       Date:  2020-10-06       Impact factor: 4.939

Review 3.  Linking autoantigen properties to mechanisms of immunity.

Authors:  J Daniel Griffin; Jimmy Y Song; Joshua O Sestak; Brandon J DeKosky; Cory J Berkland
Journal:  Adv Drug Deliv Rev       Date:  2020-04-20       Impact factor: 15.470

4.  Soluble antigen arrays disarm antigen-specific B cells to promote lasting immune tolerance in experimental autoimmune encephalomyelitis.

Authors:  Brittany L Hartwell; Chad J Pickens; Martin Leon; Laura Northrup; Matthew A Christopher; J Daniel Griffin; Francisco Martinez-Becerra; Cory Berkland
Journal:  J Autoimmun       Date:  2018-07-13       Impact factor: 7.094

5.  Soluble Antigen Arrays Displaying Mimotopes Direct the Response of Diabetogenic T Cells.

Authors:  Martin A Leon; Rebuma Firdessa-Fite; Justin K Ruffalo; Chad J Pickens; Joshua O Sestak; Remi J Creusot; Cory Berkland
Journal:  ACS Chem Biol       Date:  2019-07-01       Impact factor: 4.634

Review 6.  Therapeutic Targeting of Autoreactive B Cells: Why, How, and When?

Authors:  Zachary C Stensland; John C Cambier; Mia J Smith
Journal:  Biomedicines       Date:  2021-01-16
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.